Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
EVE Health Group Limited ( (AU:EVE) ) has shared an announcement.
EVE Health Group Limited announced significant progress in the commercial rollout of its products Dyspro™ and Libbo™. The company has completed the first patient prescriptions for Dyspro™, a cannabinoid-based gummy for women’s health issues, and placed its first commercial order for Libbo™, an oral dissolving film for erectile dysfunction. EVE has also launched an online platform, Reclaim My Cycle, to support women’s health education and prescriber resources. Additionally, a $1.1 million placement was completed to accelerate these initiatives, and a Scientific Advisory Board was established to guide the company’s evidence-based strategy.
More about EVE Health Group Limited
EVE Health Group Limited is a company operating in the health, nutrition, and wellness industry. It focuses on developing and commercializing products for women’s and men’s health, including cannabinoid-based gummies for dysmenorrhoea and endometriosis, and oral dissolving films for erectile dysfunction.
Average Trading Volume: 599,748
Technical Sentiment Signal: Sell
Current Market Cap: A$7.07M
Learn more about EVE stock on TipRanks’ Stock Analysis page.